Cargando…
Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma
Cholangiocarcinoma (CCA) is a highly malignant tumor of the hepatobiliary system that has failed to respond to many traditional therapies to a certain extent, including surgery, chemotherapy and radiotherapy. In recent years, the new therapeutic schemes based on immunology have fundamentally changed...
Autores principales: | Zhao, Li-ming, Shi, An-da, Yang, Yan, Liu, Zeng-li, Hu, Xiao-Qiang, Shu, Li-Zhuang, Tang, Yong-chang, Zhang, Zong-li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090456/ https://www.ncbi.nlm.nih.gov/pubmed/37064120 http://dx.doi.org/10.3389/fonc.2023.1140103 |
Ejemplares similares
-
Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review
por: Xie, Peiyi, et al.
Publicado: (2022) -
Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy
por: Deng, Min, et al.
Publicado: (2022) -
Association of systemic inflammation index with survival in patients with advanced perihilar cholangiocarcinoma treated with interventional therapy
por: Li, Jinyu, et al.
Publicado: (2022) -
Systemic Sequential Therapy of CisGem, Tislelizumab, and Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma Conversion Therapy
por: Ding, Yuan, et al.
Publicado: (2021) -
Adjuvant therapy for cholangiocarcinoma after surgery and prognosis factors for cholangiocarcinoma: A single-center retrospective cohort study
por: Sun, Zhongquan, et al.
Publicado: (2023)